WO2011064437A3 - Viral vectors and methods used in the preparation of gdnf - Google Patents

Viral vectors and methods used in the preparation of gdnf Download PDF

Info

Publication number
WO2011064437A3
WO2011064437A3 PCT/ES2010/070778 ES2010070778W WO2011064437A3 WO 2011064437 A3 WO2011064437 A3 WO 2011064437A3 ES 2010070778 W ES2010070778 W ES 2010070778W WO 2011064437 A3 WO2011064437 A3 WO 2011064437A3
Authority
WO
WIPO (PCT)
Prior art keywords
gdnf
preparation
viral vectors
methods used
recombinant human
Prior art date
Application number
PCT/ES2010/070778
Other languages
Spanish (es)
French (fr)
Other versions
WO2011064437A2 (en
Inventor
Eduardo Ansorena Artieda
María Soledad AYMERICH SOLER
María José BLANCO PRIETO
Erkuden Casales Zoco
Elisa Garbayo Atienza
María Carmen MOLINA SAMPER
Cristian Smerdou Picazo
Original Assignee
Proyecto De Biomedicina Cima, S.L.
Instituto Científico Y Tecnológico De Navarra, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima, S.L., Instituto Científico Y Tecnológico De Navarra, S.A. filed Critical Proyecto De Biomedicina Cima, S.L.
Publication of WO2011064437A2 publication Critical patent/WO2011064437A2/en
Publication of WO2011064437A3 publication Critical patent/WO2011064437A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to a method for the production and purification of recombinant human GDNF or a functionally equivalent variant thereof, using eukaryotic cells that contain an alphavirus vector comprising a sequence encoding recombinant human GDNF or a functionally equivalent variant thereof, operably linked to the subgenomic promoter which directs the expression of the protein in a suitable expression host. The invention also relates to alphavirus vectors and eukaryotic cells containing said alphavirus vectors.
PCT/ES2010/070778 2009-11-26 2010-11-25 Viral vectors and methods used in the preparation of gdnf WO2011064437A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200931071 2009-11-26
ES200931071 2009-11-26

Publications (2)

Publication Number Publication Date
WO2011064437A2 WO2011064437A2 (en) 2011-06-03
WO2011064437A3 true WO2011064437A3 (en) 2011-08-18

Family

ID=43902938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/070778 WO2011064437A2 (en) 2009-11-26 2010-11-25 Viral vectors and methods used in the preparation of gdnf

Country Status (1)

Country Link
WO (1) WO2011064437A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012001196A2 (en) * 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Alphaviral vectors and the uses thereof for heterologous gene expression
ES2523016B1 (en) 2013-05-20 2015-09-09 3P Biopharmaceuticals Alpha-viral vectors and cell lines for the production of recombinant proteins
CN106754755B (en) * 2015-11-23 2020-07-21 中国科学院武汉物理与数学研究所 Simplicin forest virus replicon and application thereof in sparse or fine neuron marking

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143205A1 (en) * 2001-07-20 2003-07-31 Oxford Biomedica (Uk) Limited Alphavirus expression systems
WO2008065225A2 (en) * 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Viral vector and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003978D0 (en) 1990-12-13 1990-12-13 Henrik Garoff DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
HU220795B1 (en) 1991-09-20 2002-05-28 Amgen Inc. Glialcell derived neurotrophic factor proteins and devices and pharmaceutical preparations for preventing and treating neural cell damage
GB9326271D0 (en) 1993-12-23 1994-02-23 Zeneca Ltd Expression of self-processing polyprotein in transgenic plants
EP1386926A1 (en) 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
WO2009089040A1 (en) 2008-01-11 2009-07-16 Jaffrey Samie R Methods for expressing proteins in axons

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143205A1 (en) * 2001-07-20 2003-07-31 Oxford Biomedica (Uk) Limited Alphavirus expression systems
WO2008065225A2 (en) * 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Viral vector and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EHRENGRUBER MARKUS U ET AL: "Alphaviruses: Semliki Forest virus and Sindbis virus vectors for gene transfer into neurons.", CURRENT PROTOCOLS IN NEUROSCIENCE / EDITORIAL BOARD, JACQUELINE N. CRAWLEY ... [ET AL.] OCT 2007 LNKD- PUBMED:18428656, vol. Chapter 4, October 2007 (2007-10-01), XP009148022, ISSN: 1934-8576 *
EMBORG M E ET AL: "Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 36, no. 2, 1 November 2009 (2009-11-01), pages 303 - 311, XP026676558, ISSN: 0969-9961, [retrieved on 20090804], DOI: DOI:10.1016/J.NBD.2009.07.022 *

Also Published As

Publication number Publication date
WO2011064437A2 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
WO2013063383A3 (en) Vectors encoding rod-derived cone viability factor
WO2014078688A3 (en) Recombinant adenoviruses and use thereof
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
GB2513768A (en) Complexes of cytomegalovirus proteins
MX348071B (en) Fc variants.
WO2013055888A3 (en) Recombinant human naglu protein and uses thereof
EP4223772A3 (en) Optimized factor viii gene
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
WO2010105251A3 (en) Non-integrating retroviral vector vaccines
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2013110818A3 (en) Immunogens for hiv vaccination
IN2015DN03206A (en)
MX2016009149A (en) Improved enzyme variants of lactase from kluyveromyces lactis.
WO2012047679A8 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
PH12016502554B1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
WO2011094430A3 (en) Pro-angiogenic fragments of prominin-1 and uses thereof
WO2012122378A3 (en) Antibody-like proteins for therapeutic and diagnostic use
WO2010150242A3 (en) Immunogenic streptococcus pneumoniae peptides and peptide-multimers
WO2011067758A3 (en) Immunogenic fragments and multimers from streptococcus pneumoniae proteins
WO2011064437A3 (en) Viral vectors and methods used in the preparation of gdnf
WO2012174455A3 (en) Group a streptococcus multivalent vaccine
WO2012004671A3 (en) Meganucleases variants cleaving a dna target sequence in the nanog gene and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812863

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10812863

Country of ref document: EP

Kind code of ref document: A2